Found: 13
Select item for more details and to access through your institution.
Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2014, v. 52, n. 7, p. 574, doi. 10.5414/CP201998
- By:
- Publication type:
- Article
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy.
- Published in:
- Clinical Medicine Insights: Cardiology, 2017, v. 11, p. 1, doi. 10.1177/1179546817730322
- By:
- Publication type:
- Article
Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story.
- Published in:
- Drug Design, Development & Therapy, 2021, v. 15, p. 1225, doi. 10.2147/DDDT.S289772
- By:
- Publication type:
- Article
Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
- Published in:
- Cardiology, 2022, v. 147, n. 4, p. 398, doi. 10.1159/000525883
- By:
- Publication type:
- Article
The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 7, p. 849, doi. 10.1002/cpdd.789
- By:
- Publication type:
- Article
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 3, p. 612, doi. 10.1002/ejhf.3190
- By:
- Publication type:
- Article
Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 11, p. 2060, doi. 10.1002/ejhf.2974
- By:
- Publication type:
- Article
Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study'.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 6, p. 1057, doi. 10.1002/ejhf.2074
- By:
- Publication type:
- Article
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 2, p. 277, doi. 10.1002/ejhf.2027
- By:
- Publication type:
- Article
Practice patterns of ophthalmologists administering intravitreal injections in Europe: a longitudinal survey.
- Published in:
- Clinical Ophthalmology, 2016, v. 10, p. 2485, doi. 10.2147/OPTH.S117801
- By:
- Publication type:
- Article
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 5, p. 3875, doi. 10.1002/ehf2.13541
- By:
- Publication type:
- Article
Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
- Published in:
- Neurology & Therapy, 2018, v. 7, n. 1, p. 87, doi. 10.1007/s40120-018-0097-9
- By:
- Publication type:
- Article
A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus.
- Published in:
- BMC Ophthalmology, 2012, v. 12, n. 1, p. 37, doi. 10.1186/1471-2415-12-37
- By:
- Publication type:
- Article